Well Referenced

Tag: Targeted Therapy

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs

This 2013 review discusses the pharmacology of serotonin (5-HT) receptors and highlights two selective 5-HT receptor subtype-targeted drugs: lorcaserin and pimavanserin. Lorcaserin is a 5-HT₂C receptor agonist approved for obesity treatment, promoting satiety through hypothalamic activation. Pimavanserin is a 5-HT₂A receptor inverse agonist approved for Parkinson’s disease psychosis, offering antipsychotic

Read More »
June 26, 2025 No Comments

JAK Inhibitors for Rheumatoid Arthritis

This 2023 review article provides a comprehensive overview of Janus kinase (JAK) inhibitors in the treatment of rheumatoid arthritis (RA). It discusses the mechanisms by which JAK inhibitors modulate the JAK-STAT signaling pathway to reduce inflammation and halt disease progression. The article evaluates the efficacy and safety profiles of various

Read More »
June 26, 2025 No Comments

Prospective of Colon Cancer Treatments and Scope for Combinatorial Approach to Enhanced Cancer Cell Apoptosis

This 2012 review explores current and emerging therapies for colorectal cancer, emphasizing the potential of combinatorial approaches to enhance apoptosis in cancer cells. It discusses traditional treatments like surgery and chemotherapy, as well as novel strategies involving immunotherapy, gene therapy, and targeted molecular treatments. The review highlights the role of

Read More »
June 26, 2025 No Comments

Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer

This 2022 review comprehensively examines the latest therapeutic developments for triple-negative breast cancer (TNBC), a highly aggressive and heterogeneous subtype lacking hormone receptors and HER2 expression. The article outlines current treatment paradigms including chemotherapy, and highlights advancements such as immune checkpoint inhibitors (e.g., pembrolizumab, atezolizumab) for PD-L1-positive TNBC and PARP

Read More »
June 26, 2025 No Comments

Targeting mTOR Suppressed Colon Cancer Growth Through 4EBP1/eIF4E/PUMA Pathway

This 2019 experimental study investigates how inhibition of the mammalian target of rapamycin (mTOR) pathway impedes colon cancer progression. The findings reveal that mTOR inhibition leads to the dephosphorylation of 4E-BP1, resulting in suppressed activity of eukaryotic translation initiation factor 4E (eIF4E). This suppression upregulates the expression of PUMA (p53

Read More »
June 26, 2025 No Comments

Role of Glutathione in Cancer: From Mechanisms to Therapies

This 2020 review explores the complex role of glutathione (GSH) in cancer, emphasizing its dual nature as both a protector against oxidative stress and a contributor to tumor progression and drug resistance. Elevated GSH levels in cancer cells enhance survival, proliferation, and resistance to chemotherapy by detoxifying reactive oxygen species

Read More »
June 26, 2025 No Comments

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

This 2018 review underscores the critical role of molecular testing for BRAF mutations, particularly the V600E variant, in guiding treatment strategies for advanced melanoma. Approximately 50% of advanced melanomas harbor BRAF mutations, making them amenable to targeted therapies with BRAF and MEK inhibitors, which have demonstrated significant long-term benefits. The

Read More »
June 26, 2025 No Comments

Current approaches to the management of brain metastases

This 2020 review provides a comprehensive overview of evolving strategies in the management of brain metastases (BMs), the most common intracranial tumors in adults, affecting 20–40% of patients with metastatic cancer. Advances in neuroimaging facilitate earlier and more accurate detection. Management has shifted from traditional whole-brain radiotherapy (WBRT) and neurosurgical

Read More »
June 26, 2025 No Comments